Novo Nordisk A/S Class B (0QIU)

884.90
+8.15(+0.93%)
  • Volume:
    91,452
  • Bid/Ask:
    863.10/898.30
  • Day's Range:
    884.90 - 884.90

0QIU Overview

Prev. Close
872.55
Day's Range
884.9-884.9
Revenue
167.2B
Open
880.7
52 wk Range
604.7-892.2
EPS
23.24
Volume
91,452
Market Cap
2.01T
Dividend (Yield)
11.15
(1.27%)
Average Volume (3m)
448,004
P/E Ratio
37.05
Beta
0.324
1-Year Change
22.3%
Shares Outstanding
2,260,086,820
Next Earnings Date
31 Jan 2023
What is your sentiment on Novo Nordisk B?
or
Vote to see community's results!

Novo Nordisk A/S Class B Analysis

Novo Nordisk A/S Class B Company Profile

Novo Nordisk A/S Class B Company Profile

Employees
52696
Market
Denmark

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy